Bladder transitional cell carcinoma
Not recruitingStudy on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment
Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment
- Disease:Bladder transitional cell carcinoma
- Substances:CetrelimabGemcitabine Hydrochloride
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Cetrelimab
- Sponsor:Janssen Cilag International








